ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Systemic JIA"

  • Abstract Number: 007 • 2020 Pediatric Rheumatology Symposium

    Dense Genotyping of Immunologic Loci Identifies CXCR4 as a Novel Susceptibility Locus for Systemic Juvenile Idiopathic Arthritis

    Emily Shuldiner 1, Elaine Remmers 2, Miranda Marion 3, Marc Sudman 4, Colleen Satorius 5, International Childhood Arthritis Genetics Consortium (INCHARGE), Juvenile Arthritis Consortium for the Immunochip (JACI), Wendy Thomson 6, Michael Ombrello1, Patricia Woo 7, Carl Langefeld 8, Sampath Prahalad 9 and Susan Thompson 10, 1NIAMS, NIH, Bethesda, 2National Human Genome Research Institute, Bethesda, 3Wake Forest University, Winston-Salem, 4Cincinnati Children's Hospital Medical Center, Cincinnati, 5NHGRI, NIH, Bethesda, 6Manchester Academic Health Science Centre, Manchester, United Kingdom, 7London, United Kingdom, 8Winston Salem, 9Emory + Children's Pediatric Institute, Atlanta, 10Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a severe, potentially lethal inflammatory condition. It accounts for a disproportionate share of morbidity and mortality among childhood…
  • Abstract Number: 009 • 2020 Pediatric Rheumatology Symposium

    Emapalumab (Anti-Interferon-Gamma Monoclonal Antibody) in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA)

    Fabrizio De Benedetti1, Paul Brogan 2, Claudia Bracaglia 1, Manuela Pardeo 1, Giulia Marucci 1, Emanuela Sacco 1, Despina Eleftheriou 3, Charalampia Papadopoulou 3, Alexei Grom 4, Pierre Quartier 5, Rayfel Schneider 6, Philippe Jacqmin 7, Rikke Frederiksen 8, Maria Ballabio 9 and Cristina de Min 8, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 2UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 3UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Section Head Infection, Immunology, and Rheumatology, London, United Kingdom, 4Cincinnati Children's Hospital Medical Center, Cincinnati, 5Paris-Descartes University, IMAGINE Institute, RAISE reference centre, Pediatric Immuno-Hematology and Rheumatology Unit, Necker hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, 6The Hospital for Sick Children, Toronto, Canada, 7MnS Modelling and Simulation, Dinant, Belgium, 8Swedish Orphan Biovitrum AG (Sobi), Basel, Basel-Stadt, Switzerland, 9Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland

    Background/Purpose: MAS is a severe complication of rheumatic diseases and occurs most frequently in patients with sJIA. Data from animal models and from observational studies…
  • Abstract Number: 072 • 2020 Pediatric Rheumatology Symposium

    Allogenic Hematopoietic Stem Cell Transplantation for Refractory Childhood Rheumatic Diseases

    Camille Beaufils1, Catherine Proulx 2, Annaliesse Blincoe 3, Pierre Teira 4, Henrique Bittencourt 4, Sonia Cellot 5, Michel Duval 4, Johannes Roth 6, Marie-Paule Morin 7, Jean Jacques De Bruycker 7, Julie Couture 7, Kathryn Samaan 8, Helene Decaluwe 7, Fabien Touzot 7, Elie Haddad 7 and Julie Barsalou 7, 1Division of Pediatric Rheumatology-Immunology, CHU Sainte-Justine, Montreal, Quebec, Canada, 2Department of Pediatrics, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada, 3Division of Pediatric Rheumatology-Immunology, CHU Sainte-Justine, Montreal, Canada, 4Division of Pediatric Hematology-Oncology, CHU Sainte-Justine, Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada, 5Division of Pediatric Hematology-Oncology, CHU Sainte-Justine, Department of Pediatrics, University of Montreal, Montreal, Canada, 6Division of Pediatric Rheumatology, Children Hospital of Eastern Ontario, Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada, 7Division of Pediatric Rheumatology-Immunology, CHU Sainte-Justine, Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada, 8Division of Pediatric Rheumatology-Immunology,-Allergy, CHU Sainte-Justine, Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada

    Background/Purpose: Patients with refractory rheumatic diseases face poor quality of life, long-term sequelae and life-threatening complications. With advances in allogenic hematopoietic stem cell transplantation (allo-HSCT),…
  • Abstract Number: 076 • 2020 Pediatric Rheumatology Symposium

    How Do Pediatric Rheumatologists Diagnose Macrophage Activation Syndrome in Systemic Onset Juvenile Idiopathic Arthritis? An Examination of the CARRA Registry

    Taha Moussa1, Moussa Abdelhak 2 and Cuoghi Edens 3 for the CARRA investigators, 1University of Chicago Medicine, Chicago, 2Cambridge GPVTS, Cambridge, United Kingdom, 3University of Chicago, Chicago

    Background/Purpose: Macrophage activation syndrome (MAS) is a feared complication in~ 10% of those systemic onset juvenile idiopathic arthritis (sJIA). Due to the similarity of MAS…
  • Abstract Number: 079 • 2020 Pediatric Rheumatology Symposium

    Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis

    Arianna De Matteis 1, Denise Pires Marafon 2, Ivan Caiello 2, Manuela Pardeo 2, Giulia Marucci 2, Emanuela Sacco 2, Giusi Prencipe 2, Fabrizio De Benedetti 2 and Claudia Bracaglia2, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Lazio, Italy, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy

    Background/Purpose: Macrophage Activation Syndrome (MAS) and Secondary Hemophagocytic Lymphohistiocytosis (sHLH) are hyperinflammatory conditions caused by a cytokine storm. Prompt recognition and early treatment are essential…
  • Abstract Number: 081 • 2020 Pediatric Rheumatology Symposium

    Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis

    Simone Carbogno 1, Denise Pires Marafon 2, Giulia Marucci 2, Manuela Pardeo 2, Antonella Insalaco 2, Virginia Messia 2, Emanuela Sacco 2, Ferhat Demir 3, Betul Sozeri 3, Natasia Cekada 4, Marija Jelusic 4, Olga Vougiouka 5, Mikhail Kostik 6, Alenka Gagro 7, Christoph Kessel 8, Francesca Minoia 9, Fabrizio De Benedetti 2 and Claudia Bracaglia2, 1Pediatric Area, University of Milan, Milan, Italy, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 3University of Health Sciences, Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, 4Division of Paediatric Rheumatology and Immunology, University of Zagreb, Zagreb, Croatia, 5Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Athens, Greece, 6Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, 7Children's Hospital Zagreb, Zagreb, Croatia, 8University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany, 9Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy

    Background/Purpose: Macrophage Activation Syndrome (MAS) is a severe, life-threatening, complication of rheumatic diseases in childhood, particularly of systemic Juvenile Idiopathic Arthritis (sJIA), occurring in approximately…
  • Abstract Number: 093 • 2020 Pediatric Rheumatology Symposium

    Treatment of Systemic Juvenile Idiopathic Arthritis in the CARRA Registry

    Ginger Janow 1, Timothy Beukelman 2, Yukiko Kimura 3, Rayfel Schneider 4, Shalini Mohan 5, Gail Rodich 6 and Mary Beth Son7 for the CARRA investigators, 1Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Hackensack, New Jersey, 2University of Alabama at Birmingham, Birmingham, 3Hackensack Meridian School of Medicine, Hackensack, 4The Hospital for Sick Children, Toronto, Canada, 5Genentech, Inc., South San Francisco, 6Genentech, Mill Valley, 7Boston Children's Hospital, Boston, Massachusetts

    Background/Purpose: The treatment of systemic juvenile idiopathic arthritis (SJIA) has changed dramatically over the past decade, associated with overall improvement in functional outcomes.  There may…
  • Abstract Number: 098 • 2020 Pediatric Rheumatology Symposium

    Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis

    Manuela Pardeo1, Claudia Bracaglia 1, Emanuela Sacco 1, Denise Pires Marafon 1, Antonella Insalaco 1, Giulia Marucci 1, Rebecca Nicolai 2, Virginia Messia 1 and Fabrizio De Benedetti 1, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 2IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) should be considered as a polygenic autoinflammatory disease. Interleukin 1 (IL-1) has been shown to be a major mediator…
  • Abstract Number: 140 • 2020 Pediatric Rheumatology Symposium

    Serum Biomarkers in a German Cohort of Patients with Systemic Juvenile Idiopathic Arthritis and Their Relationship to Response to Interleukin-1 Blockade

    Claas Hinze1, Tanja Hinze 2, Helmut Wittkowski 1, Christoph Kessel 1, Sabrina Fuehner 1 and Dirk Foell 1, 1University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany, 2Muenster, Nordrhein-Westfalen, Germany

    Background/Purpose: Most, but not all, patients with systemic juvenile idiopathic arthritis (systemic JIA) respond to therapy with interleukin (IL)-1 blocking agents but predictive factors have…
  • Abstract Number: 159 • 2020 Pediatric Rheumatology Symposium

    Interleukin-18 as a Key Cytokine to Understand Pathology and to Decide Appropriate Therapeutic Strategy in Chronic Arthritic Systemic Juvenile Idiopathic Arthritis

    Takako Miyamae1, Yumi Tani 1, Manabu Kawamoto 2, Takayuki Kishi 3 and Masayoshi Harigai 2, 1Pediatric Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Institute of Rheumatology, Tokyo Women's Medical University, TOKYO, Japan, 3Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: Long-term outcomes of systemic JIA are highly variable. approximately half of the patients have chronic persistent arthritis requiring extended anti-inflammatory therapy, sometimes into adulthood.…
  • Abstract Number: L06 • 2019 ACR/ARP Annual Meeting

    Interferon-gamma (IFN-γ) Neutralization with Emapalumab and Time to Response in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (s-JIA) who failed High-Dose Glucocorticoids

    Fabrizio De Benedetti1, Paul Brogan 2, Alexei A. Grom 3, Pierre Quartier 4, Rayfel Schneider 5, Jordi Antón 6, Claudia Bracaglia 7, Manuela Pardeo 8, Giulia Marucci 8, Emanuela Sacco 9, Despina Eleftheriou 10, Charalampia Papadopoulou 11, Philippe Jacqmin 12, maria ballabio 13 and Cristina de Min 13, 1Bambino Gesù Children's Hospital, Rome, Italy, 2Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, 3Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Necker Hospital, Paris, France, 5Hospital for Sick Children, Toronto, ON, Canada, 6Hospital Sant Joan de Déu, Barcelona, Spain, 7Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 8Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 9Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, 10UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Infection, Immunology, and Rheumatology section,, london, United Kingdom, 11UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Infection, Immunology, and Rheumatology section, london, United Kingdom, 12MnS, Dinant, Belgium, 13Sobi AG, basel, Switzerland

    Background/Purpose: MAS is a severe complication of rheumatic diseases, most frequently sJIA and adult-onset Still’s disease. It is characterized by fever, hepatosplenomegaly, liver dysfunction, cytopenias,…
  • Abstract Number: 780 • 2019 ACR/ARP Annual Meeting

    Changes in MiR-17-92 Cluster Expression Link Systemic Juvenile Idiopathic Arthritis, Monocyte-to-Macrophage Differentiation, and Interferon Regulation

    Divya Takellapti1, Xiaoling Niu 2, Thuy Do 3 and Grant Schulert 3, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Fudan University, Shanghai, Shanghai, China (People's Republic), 3Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: MicroRNAs (miRNAs) are small noncoding RNAs which post-transcriptionally regulate gene expression. The miR-17-92 cluster is well characterized; its overexpression has been found to serve…
  • Abstract Number: 784 • 2019 ACR/ARP Annual Meeting

    Application of Systems Biology-Based In Silico Tools for Optimal Treatment Strategy Identification in Still’s Disease

    Cristina Segu-Verges1, Mireia Coma 1, Christoph Kessel 2, Serge Smeets 3, Dirk Foell 2 and Anna Aldea 4, 1Anaxomics, Barcelona, Catalonia, Spain, 2University Hospital Muenster, Muenster, Germany, 3Novartis, Amsterdam, Netherlands, 4Novartis, Barcelona, Catalonia, Spain

    Background/Purpose: Systemic JIA (sJIA) and Adult Onset Still’s Disease may represent a disease continuum1 of the same autoinflammatory disorder, Still’s Disease. Current challenges in its…
  • Abstract Number: 813 • 2019 ACR/ARP Annual Meeting

    Monocyte and Macrophage Transcriptional Phenotypes in Systemic Juvenile Idiopathic Arthritis Reveal TRIM8 as a Mediator of IFNγ Hyperresponsiveness and Risk for Macrophage Activation Syndrome

    Grant Schulert1, Thuy Do 1, Sanjeev Dhakal 1, Ndate Fall 2, Mario Medvedovich 3, Sherry Thornton 1, Nathan salomonis 2 and Alexei A. Grom 1, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3University of Cincinnati College of Medicine, Cincinnati, OH

    Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a severe and distinct subtype of childhood arthritis. Children with SJIA are at risk for macrophage activation syndrome…
  • Abstract Number: 915 • 2019 ACR/ARP Annual Meeting

    Development and Initial Validation of the Systemic JADAS, a New Composite Disease Activity Score for Systemic Juvenile Idiopathic Arthritis

    Jessica Tibaldi1, Yasser El Miedany 2, Pryiankar Pal 3, Soamarat Vilaiyuk 4, Raju Khubchandani 5, Manuela Pardeo 6, Tapas Kumar Sabui 7, Sujata Sawhney 8, Ricardo Russo 9, Flavio Sztajnbok 10, Rolando Cimaz 11, Francesca Minoia 12, Motasem O. Alsuweiti 13, Ekaterina Alexeeva 14, Mikhail Kostik 15, Maria Cristina Maggio 16, Sulayman Al Mayouf 17, Claudia Saad 18, Giovanni Conti 19, Romina Gallizzi 20, Adele Civino 21, Masaki Shimizu 22, Enrico Felici 23, Angela Pistorio 24, Nicolino Ruperto 25, Alessandro Consolaro 26 and Angelo Ravelli 27, 1IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genoa, Italy, 2Ain Shams University, Cairo, Egypt, 3Institute of Child Health, Kolkata, India, 4Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 5Jaslok Hospital and Research Center, Mumbai, India, 6Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 7R G Kar Medical College, Kolkata, Kolkata, India, 8Department of pediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India, New Delhi, India, 9Hospital de Pediatría Garrahan, Buenos Aires, Argentina, 10Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 11University Hospital Meyer, Florence, Italy, 12Clinica De Marchi Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, 13Queen Rania Children's Hospital, Amman, Jordan, 14National Medical Research Center of Children`s Health, Moscow, Russia, 15Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, 16Università di Palermo, Dipartimento G. D'Alessandro, Palermo, Italy, 17King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, 18Hospital das Clínicas - Botucatu Medicine University, UNESP, Botucatu, Brazil, 19AOU G Martino, Messina, Italy, 20Azienda Ospedaliera Universitaria Gaetano Martino, Messina, Messina, Italy, 21Pediatric Rheumatology “Vito Fazzi” Hospital, Lecce, Lecce, Italy, 22Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa, Japan, 23SS Antonio e Biagio e Cesare Arrigo" Hospital, Alessandria, Italy, 24IRCCS Istituto Giannina Gaslini, Genova, Italy, 25Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 26Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genova, Italy, 27IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy

    Background/Purpose: The Juvenile Arthritis Disease Activity Score (JADAS) has gained increasing popularity for the measurement of the level of disease activity in patients with juvenile…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies